|Bid||1.8600 x 900|
|Ask||1.9000 x 800|
|Day's Range||1.3900 - 1.7800|
|52 Week Range||0.6180 - 6.4000|
|Beta (5Y Monthly)||3.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 07, 2022 - Mar 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.20|
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutica
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...